These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 8438418

  • 1. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts.
    Broyer M, Gagnadoux MF, Guest G, Arsan A, Beurton D, Revillon Y, Niaudet P.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):570-1. PubMed ID: 8438418
    [No Abstract] [Full Text] [Related]

  • 2. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
    Griñó JM, Castelao AM, Serón D, Gonzalez C, Galceran JM, Gil-Vernet S, Andrés E, Bover J, Torras J, Alsina J.
    Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?
    Cecka JM, Gjertson D, Terasaki PI.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):548-9. PubMed ID: 8438408
    [No Abstract] [Full Text] [Related]

  • 5. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.
    Hanto DW, Jendrisak MD, McCullough CS, So SK, Marsh JW, Rush T, Michalski S, Phelan D, Mohanakumar T.
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1050-1. PubMed ID: 1899150
    [No Abstract] [Full Text] [Related]

  • 6. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N, Hong JH, DiBenedetto A, Clayton R, Miles AM, Markell MS, Distant DA, Fleishhacker J, Sommer BG.
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract] [Full Text] [Related]

  • 7. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
    Vela C, Cristol JP, Chong G, Okamba A, Lorho R, Mion C, Mourad G.
    Transpl Int; 1994 Feb; 7 Suppl 1():S259-62. PubMed ID: 11271219
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis.
    Carrier M, Jenicek M, Pelletier LC.
    Transplant Proc; 1992 Dec; 24(6):2586-91. PubMed ID: 1465874
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF, Venkat KK, Kupin W, Dumler F, Gracida C, Uniewski M, Anaise D, Tang DH.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 15. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K, Munn SR, Sterioff S.
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract] [Full Text] [Related]

  • 16. ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial.
    Stippel DL, Arns W, Pollok M, Beckurts KT, Hesse UJ, Hölscher AH.
    Transplant Proc; 2002 Sep; 34(6):2201-2. PubMed ID: 12270362
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ, Taylor RJ, Weide LG, Sindhi R, Sudan D, Castaldo P, Cushing KA, Frisbie K, Radio SJ.
    Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation.
    Steininger R, Mühlbacher F, Hamilton G, Längle F, Gnant M, Popow T, Sautner T, Götzinger P, Wamser P, Stockenhuber F.
    Transplant Proc; 1991 Aug; 23(4):2269-71. PubMed ID: 1908154
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.